MCID: PRN009
MIFTS: 47

Paranoid Schizophrenia malady

Categories: Mental diseases

Aliases & Classifications for Paranoid Schizophrenia

Aliases & Descriptions for Paranoid Schizophrenia:

Name: Paranoid Schizophrenia 12 52 14 69
Chronic Paranoid Schizophrenia 12 69
Paranoid Type Schizophrenia Subchronic State 12
Paranoid Type Schizophrenia 12
Paraphrenic Schizophrenia 12
Schizophrenia, Paranoid 42
Paraphrenia - Late 12

Classifications:



Summaries for Paranoid Schizophrenia

Disease Ontology : 12 A schizophrenia that involves delusions or auditory hallucinations of persecution or being plotted against without thought disorder, disorganized behavior, or affective flattening.

MalaCards based summary : Paranoid Schizophrenia, also known as chronic paranoid schizophrenia, is related to schizophrenia and autism spectrum disorder. An important gene associated with Paranoid Schizophrenia is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Amphetamine addiction. The drugs Dopamine and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and brain, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 71 Paranoid schizophrenia, also called schizophrenia, paranoid type, is a sub-type of schizophrenia as... more...

Related Diseases for Paranoid Schizophrenia

Diseases related to Paranoid Schizophrenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 29.9 BDNF CCKAR COMT HTR2A MAOA MIAT
2 autism spectrum disorder 29.7 BDNF COMT SLC6A4
3 personality disorder 29.6 BDNF COMT HTR2A MAOA SLC6A4
4 cholestasis-lymphedema syndrome 10.3 COMT MAOA
5 lethal congenital contracture syndrome 1 10.2 COMT MAOA
6 teratoma with malignant transformation 10.2 BDNF HTR2A
7 conjunctival pigmentation 10.2 MAOA SLC6A4
8 hemochromatosis, type 2a 10.1 BDNF COMT MAOA
9 ornithosis 10.1 MAOA SLC6A4
10 urea cycle disorder 10.1 BDNF COMT
11 basal cell carcinoma 3 10.1 COMT HTR2A MAOA
12 dry eye syndrome 10.1 HTR2A SLC6A4
13 splenic abscess 10.1 HTR2A SLC6A4
14 adult brainstem astrocytoma 10.1 MAOA SLC6A4
15 euthyroid sick syndrome 10.1 HTR2A SLC6A4
16 renpenning syndrome 10.1 COMT MAOA SLC6A4
17 strongyloidiasis 10.1 COMT MAOA SLC6A4
18 carotid stenosis 10.1 COMT MAOA SLC6A4
19 apperceptive agnosia 10.1 COMT SLC6A4
20 nephronophthisis 13 10.1 COMT HTR2A SLC6A4
21 cholesteatoma 10.1 BDNF COMT SLC6A4
22 mucinous adenocarcinoma 10.1 BDNF MAOA SLC6A4
23 hypereosinophilic syndrome 10.0 BDNF MAOA SLC6A4
24 neurogenic bladder 10.0 HTR2A MAOA SLC6A4
25 pyromania 10.0 HTR2A MAOA SLC6A4
26 kidney pelvis papillary carcinoma 10.0 MAOA SLC6A4
27 hepatitis b reinfection following liver transplantation 10.0 HTR2A MAOA SLC6A4
28 alzheimer disease 17 10.0 HTR2A SLC6A4 TPH2
29 microcephaly 13, primary, autosomal recessive 10.0 HTR2A MAOA SLC6A4
30 bartter disease 10.0 HTR2A SLC6A4 TPH2
31 epithelioid type angiomyolipoma 10.0 BDNF HTR2A SLC6A4
32 waardenburg's syndrome 10.0 HTR2A SLC6A4
33 chronic eosinophilic pneumonia 10.0 BDNF COMT MAOA SLC6A4
34 delusional disorder 10.0
35 colorectal adenocarcinoma 10.0 COMT MAOA SLC6A4 TPH2
36 lichen disease 9.9 COMT HTR2A MAOA SLC6A4
37 primary angle-closure glaucoma 9.9 BDNF COMT HTR2A SLC6A4
38 chagas disease 9.9 BDNF COMT HTR2A SLC6A4
39 hypoglycemic coma 9.9 BDNF HTR2A MAOA SLC6A4
40 postencephalitic parkinson disease 9.9 BDNF HTR2A MAOA SLC6A4
41 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 9.9 BDNF COMT HTR2A SLC6A4
42 chronic conjunctivitis 9.9 BDNF COMT HTR2A SLC6A4
43 tinea pedis 9.9 MAOA SLC6A4
44 epilepsy 9.9
45 klinefelter's syndrome 9.9
46 mutism 9.9
47 cytomegalic congenital adrenal hypoplasia 9.8 BDNF COMT HTR2A MAOA SLC6A4
48 hereditary multiple exostoses 9.8 BDNF COMT HTR2A MAOA SLC6A4
49 cecal benign neoplasm 9.8 COMT HTR2A MAOA SLC6A4 TPH2
50 brain glioblastoma multiforme 9.8 BDNF COMT HTR2A SLC6A4 TPH2

Comorbidity relations with Paranoid Schizophrenia via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Alzheimer Disease
Deficiency Anemia Delusional Disorder
Hypertension, Essential Hypothyroidism
Paranoid Personality Disorder Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophrenia
Schizophreniform Disorder Tardive Dyskinesia

Graphical network of the top 20 diseases related to Paranoid Schizophrenia:



Diseases related to Paranoid Schizophrenia

Symptoms & Phenotypes for Paranoid Schizophrenia

MGI Mouse Phenotypes related to Paranoid Schizophrenia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.76 BDNF CCKAR COMT HTR2A MAOA SLC18A1
2 nervous system MP:0003631 9.5 COMT MAOA SLC18A1 SLC6A4 TPH2 BDNF
3 taste/olfaction MP:0005394 8.8 BDNF CCKAR TPH2

Drugs & Therapeutics for Paranoid Schizophrenia

Drugs for Paranoid Schizophrenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
2
Olanzapine Approved, Investigational Phase 4,Phase 2 132539-06-1 4585
3
Risperidone Approved, Investigational Phase 4,Phase 2 106266-06-2 5073
4
Diazepam Approved, Illicit, Vet_approved Phase 4 439-14-5 3016
5
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
6
Haloperidol Approved Phase 4 52-86-8 3559
7
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
8
Ziprasidone Approved Phase 4 146939-27-7 60854
9
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
Cycloserine Approved Phase 4 68-41-7 401 6234
12
Cinnarizine Approved Phase 4 298-57-7 2761 1547484
13
Thiamine Approved, Nutraceutical, Vet_approved Phase 4 59-43-8 1130
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
15
decanoic acid Experimental Phase 4 334-48-5 2969
16
Serotonin Phase 4,Phase 2 50-67-9 5202
17 Serotonin Agents Phase 4,Phase 2
18 Serotonin Antagonists Phase 4,Phase 2
19 Serotonin Uptake Inhibitors Phase 4,Phase 2
20 Gastrointestinal Agents Phase 4,Phase 2
21 Neurotransmitter Agents Phase 4,Phase 2
22 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
23 Tranquilizing Agents Phase 4,Phase 3,Phase 2
24 Peripheral Nervous System Agents Phase 4,Phase 2
25 Dopamine Agents Phase 4,Phase 2
26 Dopamine Antagonists Phase 4,Phase 2
27 Antiemetics Phase 4,Phase 2
28 Psychotropic Drugs Phase 4,Phase 3,Phase 2
29 Antipsychotic Agents Phase 4,Phase 3,Phase 2
30 Autonomic Agents Phase 4,Phase 2
31 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
32 Haloperidol decanoate Phase 4
33 Quetiapine Fumarate Phase 4,Phase 2 111974-72-2
34
Histamine Phosphate Phase 4 51-74-1 65513
35 Analgesics Phase 4
36 calcium channel blockers Phase 4
37 Adjuvants, Anesthesia Phase 4
38 N-Methylaspartate Phase 4
39 Adrenergic Agents Phase 4
40 GABA Agents Phase 4
41 GABA Modulators Phase 4
42 Adrenergic Agonists Phase 4
43 Neuromuscular Agents Phase 4
44 Adrenergic alpha-2 Receptor Agonists Phase 4
45 Adrenergic alpha-Agonists Phase 4
46 Analgesics, Non-Narcotic Phase 4
47 Histamine Antagonists Phase 4
48 Histamine H1 Antagonists Phase 4
49 Trace Elements Phase 4
50 Anesthetics Phase 4

Interventional clinical trials:

(show all 43)
id Name Status NCT ID Phase
1 Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia Completed NCT00742079 Phase 4
2 A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis Completed NCT00644800 Phase 4
3 Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA) Completed NCT00246194 Phase 4
4 Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids Completed NCT00205712 Phase 4
5 Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet Completed NCT00324051 Phase 4
6 Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis Completed NCT01939093 Phase 4
7 D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions Recruiting NCT01981759 Phase 4
8 Integrated Care in Psychotic Disorders With Severe Mental Illness Recruiting NCT01888627 Phase 4
9 Trial of Cognitive Behavioral Therapy for Schizophrenia Unknown status NCT00300651 Phase 3
10 Intranasal Oxytocin in Schizophrenia Patients Unknown status NCT01987050 Phase 3
11 Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896) Completed NCT01190254 Phase 3
12 Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897) Completed NCT01190267 Phase 3
13 Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis Unknown status NCT00465920 Phase 2
14 MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) Completed NCT00506077 Phase 2
15 MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027) Completed NCT00482430 Phase 2
16 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia Completed NCT01176721 Phase 2
17 The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia Completed NCT02408198 Phase 2
18 Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia Completed NCT00103727 Phase 2
19 Enhancing Recovery in Early Schizophrenia Recruiting NCT02926859 Phase 2
20 A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients Recruiting NCT02088060 Phase 2
21 Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia Active, not recruiting NCT02787122 Phase 2
22 Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone Unknown status NCT00563017
23 Cognitive Determinants of Psychoeducation and Information in Psychoses Unknown status NCT00646256
24 Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus Unknown status NCT00222807
25 Cognitive Behavioral Therapy for Paranoia in Schizophrenia Unknown status NCT01704833
26 Cross-Sectional Iloperidone IVGTT Unknown status NCT01686815
27 The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis Unknown status NCT01565174
28 Cognitive Behavioral Therapy for the Prevention of Paranoia in Adolescents at High Risk Unknown status NCT01923701
29 Acceptance and Commitment Therapy for Delusions Completed NCT00657631
30 Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. Completed NCT00716755
31 Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis Completed NCT01216891
32 Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial Completed NCT01920685
33 Oxytocin Treatment of Schizophrenia Completed NCT01028677
34 Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy Completed NCT00791440
35 Clinical and Genetic Factors Associated With Psychotic Symptoms Among Cocaine Abusers Completed NCT01569347
36 Prevention of Weight Gain in Early Psychoses Completed NCT01075295
37 Lifestyle Intervention for Diabetes and Weight Management in Psychosis Completed NCT01828931
38 Characterization of Emotional Processing of Information in Bipolar Disorder and Schizophrenic Patients Recruiting NCT02841345
39 Improving Work Outcome for People With Severe Mental Illness Active, not recruiting NCT01722344
40 Oxytocin Add on Study for Stable Schizophrenic Patients Suspended NCT00506909
41 Antipsychotic Effects of Oxytocin Suspended NCT01621737
42 Anticholinergic Burden in Schizophrenia Terminated NCT00715377
43 Schizophrenic Patients Taking Part in Integrated Care Program Terminated NCT00617214

Search NIH Clinical Center for Paranoid Schizophrenia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: schizophrenia, paranoid

Genetic Tests for Paranoid Schizophrenia

Anatomical Context for Paranoid Schizophrenia

MalaCards organs/tissues related to Paranoid Schizophrenia:

39
Testes, Eye, Brain, Pituitary, Thyroid, Cortex, Amygdala

Publications for Paranoid Schizophrenia

Articles related to Paranoid Schizophrenia:

(show top 50) (show all 297)
id Title Authors Year
1
Association of the IFN-I^ (+874A/T) Genetic Polymorphism with Paranoid Schizophrenia in Tunisian Population. ( 27819519 )
2017
2
Discriminating between first- and second-order cognition in first-episode paranoid schizophrenia. ( 28005458 )
2016
3
Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder. ( 27391238 )
2016
4
IFNGR2 genetic polymorphism associated with sex-specific paranoid schizophrenia risk. ( 27563937 )
2016
5
Variants in TERT influencing telomere length are associated with paranoid schizophrenia risk. ( 26799699 )
2016
6
GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia: A post-mortem study. ( 26922657 )
2016
7
Huntington's disease in a patient with 15-year history of Capgras delusion misdiagnosed as paranoid schizophrenia. ( 26719104 )
2016
8
[The Role of Neurotrophins and Neurexins Genes in the Risk of Paranoid Schizophrenia in Russians and Tatars]. ( 26410934 )
2015
9
Long term telemedicine study of compliance in paranoid schizophrenia. ( 26417777 )
2015
10
Abnormal inter- and intra-hemispheric integration in male paranoid schizophrenia: a graph-theoretical analysis. ( 26300598 )
2015
11
Genetic variants in long non-coding RNA MIAT contribute to risk of paranoid schizophrenia in a Chinese Han population. ( 26004688 )
2015
12
Increased density of DISC1-immunoreactive oligodendroglial cells in fronto-parietal white matter of patients with paranoid schizophrenia. ( 26315603 )
2015
13
Evidence from paranoid schizophrenia for more than one component of theory of mind. ( 26579026 )
2015
14
Spinocerebellar ataxia-10 with paranoid schizophrenia. ( 25745322 )
2015
15
Paranoid Schizophrenia versus Schizoaffective Disorder: Neuropsychological Aspects. ( 26506747 )
2015
16
Chronic non-fatal Datura abuse in a patient of paranoid schizophrenia: a case report. ( 25544354 )
2015
17
Secondary association of PDLIM5 with paranoid schizophrenia in Emirati patients. ( 26925374 )
2015
18
A paired case-control comparison of ziprasidone on visual sustained attention and visual selective attention in patients with paranoid schizophrenia. ( 26367712 )
2015
19
A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia. ( 25948854 )
2015
20
Subjective experience of emotions and emotional empathy in paranoid schizophrenia. ( 25288043 )
2014
21
Rapid Response of Long-Standing, Treatment-Resistant Non-Catatonic Mutism in Paranoid Schizophrenia with Single ECT session. ( 25535609 )
2014
22
Alcohol abuse as the strongest risk factor for violent offending in patients with paranoid schizophrenia. ( 24778102 )
2014
23
Facial emotion recognition in paranoid schizophrenia and autism spectrum disorder. ( 25278104 )
2014
24
Decreased resting-state interhemispheric coordination in first-episode, drug-naive paranoid schizophrenia. ( 24075897 )
2014
25
Demographic features and premorbid personality disorder traits in relation to age of onset and sex in paranoid schizophrenia. ( 24495576 )
2014
26
Hiccups associated with switching from olanzapine to aripiprazole in a patient with paranoid schizophrenia. ( 24824665 )
2014
27
[Glutamate receptors genes polymorphism and the risk of paranoid schizophrenia in Russians and tatars from the Republic of Bashkortostan]. ( 25842862 )
2014
28
[The association of polymorphisms in SLC18A1, TPH1 and RELN genes with risk of paranoid schizophrenia]. ( 25842846 )
2014
29
Genetic association between the dopamine D1-receptor gene and paranoid schizophrenia in a northern Han Chinese population. ( 24790447 )
2014
30
EEG Theta Power and Coherence to Octave Illusion in First-Episode Paranoid Schizophrenia with Auditory Hallucinations. ( 25359515 )
2014
31
Cognitive restructuring and graded behavioural exposure for delusional appraisals of auditory hallucinations and comorbid anxiety in paranoid schizophrenia. ( 25302129 )
2014
32
Relationship between genetic polymorphisms in the DRD5 gene and paranoid schizophrenia in northern Han Chinese. ( 24668635 )
2014
33
Is the comprehension of idiomatic sentences indeed impaired in paranoid Schizophrenia? A window into semantic processing deficits. ( 25346676 )
2014
34
Ribosomal DNA transcription in the dorsal raphe nucleus is increased in residual but not in paranoid schizophrenia. ( 25091423 )
2014
35
TPH2 gene polymorphisms in the regulatory region are associated with paranoid schizophrenia in Northern Han Chinese. ( 24668623 )
2014
36
Clozapine induced tubulointerstitial nephritis in a patient with paranoid schizophrenia. ( 24849641 )
2014
37
The interaction of BDNF and NTRK2 gene increases the susceptibility of paranoid schizophrenia. ( 24069289 )
2013
38
Kallmann syndrome and paranoid schizophrenia: a rare combination. ( 23329708 )
2013
39
Apparent motion perception in patients with paranoid schizophrenia. ( 22865160 )
2013
40
Lack of association of IL-6 (-174 G>C) and TNF-I+ (-238 G>A) variants with paranoid schizophrenia in Indian Bengalee population. ( 23265967 )
2013
41
Zotepine-induced convulsive seizures in a chronic case of treatment resistant paranoid schizophrenia. ( 23543675 )
2013
42
[Association polymorphic variants of GRIN2B gene with paranoid schizophrenia and response to common neuroleptics in Russians and Tatars from Bashkortostan Republic]. ( 25486778 )
2013
43
Distinct structural alterations independently contributing to working memory deficits and symptomatology in paranoid schizophrenia. ( 23040316 )
2013
44
Relationship between genetic polymorphisms in the HTR1A gene and paranoid schizophrenia in a northern Han Chinese population. ( 23192369 )
2013
45
History of Religious Delusions and Psychosocial Functioning Among Mexican Patients with Paranoid Schizophrenia. ( 23674244 )
2013
46
Theory of Mind differences in older patients with early-onset and late-onset paranoid schizophrenia. ( 23319414 )
2013
47
Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFI+) gene polymorphisms with paranoid schizophrenia in a Polish population. ( 23487197 )
2013
48
Challenges in managing a mother with a dual diagnosis of peripartum cardiomyopathy and paranoid schizophrenia - a case report. ( 23742788 )
2013
49
Heat shock protein 70 gene polymorphisms are associated with paranoid schizophrenia in the Polish population. ( 23893339 )
2013
50
Abnormal auditory sensory gating-out in first-episode and never-medicated paranoid schizophrenia patients: an fMRI study. ( 23820976 )
2013

Variations for Paranoid Schizophrenia

Expression for Paranoid Schizophrenia

Search GEO for disease gene expression data for Paranoid Schizophrenia.

Pathways for Paranoid Schizophrenia

Pathways related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.77 BDNF HTR2A MAOA SLC6A4 TPH2
2
Show member pathways
11.68 BDNF MAOA SLC18A1
3 11.41 HTR2A MAOA SLC18A1 SLC6A4 TPH2
4
Show member pathways
11.16 COMT SLC6A4
5
Show member pathways
11.13 MAOA SLC6A4 TPH2
6
Show member pathways
10.86 COMT MAOA SLC6A4
7
Show member pathways
10.8 COMT MAOA
8 10.55 COMT MAOA
9
Show member pathways
10.51 COMT MAOA
10 10.37 HTR2A MAOA SLC6A4 TPH2

GO Terms for Paranoid Schizophrenia

Biological processes related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neurotransmitter transport GO:0006836 9.4 SLC18A1 SLC6A4
2 neurotransmitter catabolic process GO:0042135 9.37 COMT MAOA
3 catecholamine metabolic process GO:0006584 9.32 COMT MAOA
4 monoamine transport GO:0015844 9.26 SLC18A1 SLC6A4
5 dopamine catabolic process GO:0042420 9.16 COMT MAOA
6 regulation of hormone secretion GO:0046883 8.96 CCKAR HTR2A
7 serotonin transport GO:0006837 8.62 SLC18A1 SLC6A4

Molecular functions related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 monoamine transmembrane transporter activity GO:0008504 8.96 SLC18A1 SLC6A4
2 serotonin transmembrane transporter activity GO:0015222 8.62 SLC18A1 SLC6A4

Sources for Paranoid Schizophrenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....